Loading...
OTCM
GLAXF
Market cap101bUSD
Jun 18, Last price  
25.70USD
1D
-2.04%
1Q
-1.44%
Jan 2017
6.20%
Name

GSK plc

Chart & Performance

D1W1MN
OTCM:GLAXF chart
P/E
30.29
P/S
2.49
EPS
0.64
Div Yield, %
2.23%
Shrs. gr., 5y
15.60%
Rev. gr., 5y
-1.45%
Revenues
31.38b
+3.46%
21,660,000,00023,225,000,00022,716,000,00024,352,000,00028,368,000,00028,392,000,00027,387,000,00026,431,000,00026,505,000,00023,006,000,00023,923,000,00027,889,000,00030,186,000,00030,821,000,00033,754,000,00034,099,000,00034,114,000,00029,324,000,00030,328,000,00031,376,000,000
Net income
2.58b
-47.75%
4,689,000,0005,389,000,0005,214,000,0004,712,000,0005,531,000,0001,634,000,0005,261,000,0004,565,000,0005,436,000,0002,756,000,0008,422,000,000912,000,0001,532,000,0003,623,000,0004,645,000,0005,749,000,0004,385,000,0004,921,000,0004,928,000,0002,575,000,000
CFO
6.55b
-3.16%
5,587,000,0003,958,000,0005,795,000,0007,311,000,0007,841,000,0006,797,000,0006,250,000,0004,375,000,0007,222,000,0005,176,000,0002,569,000,0006,497,000,0006,918,000,0008,421,000,0008,020,000,0008,441,000,0007,952,000,0007,403,000,0006,768,000,0006,554,000,000
Dividend
Aug 15, 20240.192 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.
IPO date
May 22, 1972
Employees
69,400
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT